| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease that causes respiratory and cardiac failure. Inflammation is involved in the pathogenesis of muscular dystrophy and therefore immunosuppressants can be utilized to improve muscle function. For cell therapeutic approach, multipotent mesenchymal stromal cells (MSCs) are promising because of their immunosuppressive properties and ability to differentiate into myogenic-lineage. In this study, we demonstrated that the correlations of inflammation with the severity of DMD by the results of dystrophic mice, which exhibited more severe inflammation and cardiorespiratory dysfunction by genetic ablation of IL-10. We established safe and effective cell transplantation of MSCs into DMD dogs and also indicated the effects of IL-10 on the MSCs engraftment in the skeletal muscle. The strategy would be promising for the anti-inflammatory therapy of DMD, although further study is required for the mechanism of interaction.
|
